Vishal Sikri
President at Inivata Ltd.
Net worth: 2 M $ as of 2024-04-29
Profile
Vishal Sikri is currently the President & Chief Commercial Officer at Inivata Ltd.
He previously worked as the President-Advanced Diagnostics at NeoGenomics, Inc. from 2022 to 2024.
Mr. Sikri has an undergraduate degree from Beloit College, an MBA from Loyola University of Chicago, and a graduate degree from the University of Wisconsin.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
NEOGENOMICS, INC.
0.10% | 2024-03-24 | 129,085 ( 0.10% ) | 2 M $ | 2024-04-29 |
Vishal Sikri active positions
| Companies | Position | Start |
|---|---|---|
Inivata Ltd.
 Inivata Ltd. Packaged SoftwareTechnology Services Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom. | President | 2022-05-22 |
Former positions of Vishal Sikri
| Companies | Position | End |
|---|---|---|
| NEOGENOMICS, INC. | Corporate Officer/Principal | 2024-04-14 |
Training of Vishal Sikri
| Beloit College | Undergraduate Degree |
| University of Wisconsin | Graduate Degree |
| Loyola University of Chicago | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| NEOGENOMICS, INC. | Health Services |
| Private companies | 1 |
|---|---|
Inivata Ltd.
Inivata Ltd. Packaged SoftwareTechnology Services Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom. | Technology Services |
- Stock Market
- Insiders
- Vishal Sikri
